NASDAQ · LRMR
Healthcare · Biotechnology
$2.24
Down-$0.11 (-4.68%)
Updated Oct 27, 2026, 5:18 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LRMR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
LRMR closed at $2.24 after 21 trading sessions, down 29.34% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $2.35 | $2.39 | $2.18 | $2.24 | 1.31M |
| Oct 23, 2026 | $2.27 | $2.37 | $2.22 | $2.35 | 1.14M |
| Oct 22, 2026 | $2.40 | $2.5092 | $2.235 | $2.27 | 1.76M |
| Oct 21, 2026 | $2.40 | $2.54 | $2.39 | $2.42 | 1.51M |
| Oct 20, 2026 | $2.12 | $2.49 | $2.10 | $2.44 | 1.81M |
| Oct 19, 2026 | $1.99 | $2.175 | $1.96 | $2.12 | 1.23M |
| Oct 16, 2026 | $2.05 | $2.07 | $1.915 | $1.985 | 1.69M |
| Oct 15, 2026 | $2.09 | $2.115 | $1.95 | $1.99 | 6.18M |
| Oct 14, 2026 | $2.15 | $2.22 | $2.06 | $2.09 | 2.26M |
| Oct 13, 2026 | $2.53 | $2.53 | $2.13 | $2.16 | 2.57M |
| Oct 12, 2026 | $2.66 | $2.69 | $2.53 | $2.53 | 952.18K |
| Oct 9, 2026 | $2.68 | $2.74 | $2.62 | $2.67 | 868.88K |
| Oct 8, 2026 | $2.72 | $2.74 | $2.61 | $2.70 | 1.19M |
| Oct 7, 2026 | $2.77 | $2.835 | $2.72 | $2.75 | 717.99K |
| Oct 6, 2026 | $2.88 | $2.90 | $2.74 | $2.78 | 829.23K |
| Oct 5, 2026 | $2.96 | $3.04 | $2.775 | $2.86 | 886.14K |
| Oct 2, 2026 | $3.11 | $3.11 | $2.92 | $2.96 | 835.02K |
| Oct 1, 2026 | $3.20 | $3.20 | $3.04 | $3.06 | 858.31K |
| Sep 30, 2026 | $3.13 | $3.225 | $3.075 | $3.195 | 1.5M |
| Sep 29, 2026 | $3.13 | $3.20 | $3.115 | $3.14 | 1.04M |
| Sep 28, 2026 | $3.04 | $3.2308 | $3.03 | $3.17 | 1.67M |
The latest Smart Investors Daily articles mentioning LRMR.
Company
Market Activity
Research & News
LRMR research
Company profile and research snapshot.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Wedbush | Outperform | — |
| Jun 30, 2026 | Baird | Outperform | — |
| May 27, 2026 | JP Morgan | Overweight | — |
| May 18, 2026 | Wedbush | Outperform | — |
| Mar 20, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 5, 2026
The heavy selling pressure might have exhausted for Larimar (LRMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Yahoo · Sep 29, 2026
BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development ex
Benzinga · Sep 29, 2026
Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and
Yahoo · Sep 9, 2026
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors. Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LRMR.
